| Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy | 09/09 07:00 | businesswire.com |
| Why NovoCure Stock Dived by 13% This Week | 09/06 17:19 | fool.com |
| Wall Street Analysts Think NovoCure (NVCR) Could Surge 35.96%: Read This Before Placing a Bet | 08/16 11:01 | zacks.com |
| New Strong Buy Stocks for August 1st | 08/01 08:21 | zacks.com |
| Wall Street Analysts Believe NovoCure (NVCR) Could Rally 26.39%: Here's is How to Trade | 07/30 10:56 | zacks.com |
| NovoCure Limited: A Post Q2 Analysis | 07/26 12:34 | seekingalpha.com |
| NovoCure Limited (NVCR) Q2 2024 Earnings Call Transcript | 07/25 12:35 | seekingalpha.com |
| NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates | 07/25 09:10 | zacks.com |
| METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival | 06/03 08:00 | businesswire.com |
| TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany | 05/23 17:05 | businesswire.com |